{"entity":{"id":"nct06055439","kind":"trial","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","aka":[],"tldr":"A phase 1/2 trial of CHM-2101 CAR-T cells in neuroendocrine tumours, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Chimeric Therapeutics, now recruiting.","summary":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy is a phase 1/2 interventional study registered as NCT06055439 by Chimeric Therapeutics, with 135 participants planned, started 2024-05-15 and due to reach its primary completion in 2026-05. Interventions recorded: CHM-2101 CAR-T cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06055439","url":"https://clinicaltrials.gov/study/NCT06055439"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine","colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06055439","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers","sponsor":"Chimeric Therapeutics","enrolled":135,"outcomes":[]},"route":"/trials/nct06055439/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}]}}